EX-99.1 2 tm2530148d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports Third Quarter 2025 Financial Results Third quarter revenue increased 15% year-over-year to $44.2 million Commercial Cell & Gene Therapy revenue increased 36% year-over-year to $8.3 million Life Sciences Services revenue grew 16% year-over-year, including a 21% rise in BioStorage/BioServices revenue Life Sciences Products revenue grew 15% year-over-year Company updates full year 2025 revenue guidance of $170 to $174 million NASHVILLE, Tennessee, November 4, 2025, - Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2025. Provided in this press release are financial performance highlights, an update to our annual revenue guidance for 2025 and access information for today’s earnings conference call. Jerrell Shelton, CEO of Cryoport, commented, “Q3 was another outstanding quarter for Cryoport with 15% year-over-year growth in revenue from continuing operations. During the third quar…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
CryoPort, Inc.
CYRXNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 4, 2025, Cryoport, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release issued by the Company is attached hereto as Exhibit 99.1.…
Company context
Cryoport, Inc. (Nasdaq: CYRX) is a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized BioLogistics, BioStorage, BioServices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine™."